10-Q: PURE Bioscience Reports Q2 2025 Results: Revenue Declines, Losses Persist Amidst Going Concern Uncertainty

PURE Bioscience reports a net loss of $1.487 million on net revenue of $947,000 for the six months ended January 31, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• PURE Bioscience, Inc. reported its financial results for the quarterly period ended January 31, 2025.
• The company's net product sales for the six months ended January 31, 2025, were $946,000, a decrease from $1,043,000 in the same period of 2024.
• Total revenue for the six months ended January 31, 2025, was $947,000, compared to $1,048,000 for the six months ended January 31, 2024.
• The company's net loss for the six months ended January 31, 2025, was $1,487,000, compared to a net loss of $1,737,000 for the six months ended January 31, 2024.
• Basic and diluted net loss per share was $ (0.01 ) for the six months ended January 31, 2025, the same as the three months ended January 31, 2024.
• The company's cash and cash equivalents decreased from $349,000 as of July 31, 2024, to $202,000 as of January 31, 2025.
• The company has a stockholders deficiency of $4,267,000 as of January 31, 2025.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• The company will need to continue to fund its operations with the proceeds of offerings of its equity and debt securities.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with declining sales, persistent losses, and a going concern warning. While there are some improvements in reducing losses and expenses, the overall outlook is negative.

Positives

• The net loss decreased by $250,000 for the six months ended January 31, 2025, compared to the same period in 2024.
• Selling, general and administrative expenses decreased by $386,000 for the six months ended January 31, 2025, compared to the same period in 2024.
• Gross margin as a percentage of net product sales, or gross margin percentage, was 58% for the six months ended January 31, 2025.

Negatives

• Net product sales decreased by $97,000 for the six months ended January 31, 2025, compared to the same period in 2024.
• The company has a history of recurring losses and a stockholders deficiency of $4,267,000 as of January 31, 2025.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• Cash and cash equivalents decreased from $349,000 as of July 31, 2024, to $202,000 as of January 31, 2025.

Risks

• The company's future capital requirements depend on numerous forward-looking factors, including the acceptance of its products, regulatory approvals, and the costs of developing new products.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• The company may need to raise additional capital through offerings of equity or debt securities, which could result in substantial dilution to existing stockholders or restrictive covenants.
• The company's results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future.
• The company's existing cash resources are not sufficient to meet its anticipated needs over the next twelve months.

Future Outlook

The company's future capital requirements depend on numerous forward-looking factors, including the acceptance of its products, regulatory approvals, and the costs of developing new products. The company will need to continue to fund its operations with the proceeds of offerings of its equity and debt securities.

Management Comments

• We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control.
• Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform.
• We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain.

Industry Context

The company operates in the antimicrobial solutions market, which is driven by increasing concerns about food safety and hygiene. The company's SDC-based products compete with other sanitizers and disinfectants in the food industry and personal care markets.

Comparison to Industry Standards

• It is difficult to compare PURE Bioscience directly to industry standards due to its unique SDC technology and focus on specific applications.
• However, companies like Ecolab and Steris offer broader ranges of sanitation and hygiene products and services, often with greater financial resources and market reach.
• PURE Bioscience's financial performance lags behind these larger competitors, as evidenced by its recurring losses and reliance on external financing.
• Smaller, specialized companies in the antimicrobial space may offer more relevant comparisons, but detailed financial data for these firms is often not publicly available.

Related Party Transactions

• Tom Y. Lee, a member of the company's Board of Directors, invested $500,000 in the 2025 Private Placement, through affiliates or directly.
• On June 21, 2024, the Company issued an additional 2024 Note to Mr. Lee pursuant to the 2024 Note Purchase Agreement in a subsequent closing with an aggregate principal of $500,000.
• Messrs. Tom Y. Lee and Ivan Chen, each a member of the Company’s Board invested $1,000,000 and $15,000 , as of July 31, 2023, respectively in the 2023 Private Placement, through affiliates or directly.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern status.
• Customers may be concerned about the company's ability to continue supplying products.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to grow and support its distribution network.
• The company plans to continue to partner with third parties seeking approvals to market SDC-based products outside the U.S.
• The company plans to develop additional proprietary products and applications.
• The company plans to protect and enhance its intellectual property.

Key Dates